iX Biopharma Ltd. (SGX:42C)

Singapore · Delayed Price · Currency is SGD

0.4150

+0.0300 (7.79%)

Jul 21, 2026, 4:12 PM SGT

2,084% (1Y)

Market Cap	419.33M +2,385.5%
Revenue (ttm)	7.00M -2.4%
Net Income	-4.67M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,123,000
Open	0.3800
Previous Close	0.3850
Day's Range	0.3800 - 0.4200
52-Week Range	0.0180 - 0.4600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2004

Employees 35

Stock Exchange Singapore Exchange

Ticker Symbol 42C

Full Company Profile

Financial Performance

In fiscal year 2025, iX Biopharma's revenue was 7.77 million, an increase of 30.34% compared to the previous year's 5.96 million. Losses were -10.14 million, -6.05% less than in 2024.

Financial Statements